Alzheimer's disease (AD) is the commonest neurodegenerative disease and the most
frequent cause of dementia. It affects 30 million people worldwide. Current research criteria …

Plasma levels of tau phosphorylated at threonine-217 (p-tau217) is a candidate tool to
monitor Alzheimer's disease. We studied 150 cognitively unimpaired participants and 100 …

The rate of progression from Mild Cognitive Impairment (MCI) to Alzheimer's disease (AD) is
estimated at> 10% per year, reaching up to 80–90% after 6 years. MCI is considered an …

Higher body mass index (BMI) in late-life has recently been considered as a possible
protective factor for Alzheimer's disease (AD), which yet remains conflicting. To test this …

We examined if plasma phosphorylated tau is associated with neurodegeneration in
Alzheimer's disease. We investigated 372 cognitively unimpaired participants, 554 mild …

Background Magnetic resonance imaging (MRI) has unveiled specific alterations at different
stages of Alzheimer's disease (AD) pathophysiologic continuum constituting what has been …

Prevention and early treatment strategies for Alzheimer's disease (AD) are hampered by the
lack of research biomarkers. Neuropathological changes in the Locus Coeruleus (LC) are …

Background: Many parts of the brain experience excruciating pain as a result of Alzheimer's
disease, a form of dementia. Cognitive processes and neuropsychiatric regulation are …

Abstract The COMT Val 158 Met polymorphism has recently been identified as a predictor
for cognitive decline in Parkinson's disease (PD). However, it remains unknown whether an …

Cerebrospinal fluid (CSF) YKL40 and sTREM2 are astroglial and microglial activity
biomarkers, respectively. We assessed whether CSF YKL40 and sTREM2 baseline levels …